company background image
VRPX

Virpax Pharmaceuticals NasdaqCM:VRPX Stock Report

Last Price

US$1.66

Market Cap

US$19.4m

7D

-0.6%

1Y

-64.1%

Updated

11 Aug, 2022

Data

Company Financials +
VRPX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

VRPX Stock Overview

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.

Virpax Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Virpax Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.66
52 Week HighUS$36.00
52 Week LowUS$1.19
Beta0
1 Month Change2.47%
3 Month Change23.88%
1 Year Change-64.07%
3 Year Changen/a
5 Year Changen/a
Change since IPO-74.58%

Recent News & Updates

Shareholder Returns

VRPXUS PharmaceuticalsUS Market
7D-0.6%-0.3%1.2%
1Y-64.1%3.2%-11.6%

Return vs Industry: VRPX underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: VRPX underperformed the US Market which returned -11.6% over the past year.

Price Volatility

Is VRPX's price volatile compared to industry and market?
VRPX volatility
VRPX Average Weekly Movement8.1%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: VRPX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: VRPX's weekly volatility has decreased from 41% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20167Tony Mackhttps://www.virpaxpharma.com

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company’s preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.

Virpax Pharmaceuticals, Inc. Fundamentals Summary

How do Virpax Pharmaceuticals's earnings and revenue compare to its market cap?
VRPX fundamental statistics
Market CapUS$19.45m
Earnings (TTM)-US$14.81m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VRPX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$14.81m
Earnings-US$14.81m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.26
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did VRPX perform over the long term?

See historical performance and comparison